911, 2021
NTRK inhibitors, a successful example of a tissue-agnostic approach in anticancer targeted therapy
In the last three years, two TRK inhibitors, larotrectinib and [...]
2209, 2021
KRAS, a new weapon for the fight against lung cancer and more
Between May and June 2021, two KRAS G12C inhibitors received [...]
3006, 2021
Lung cancer: molecular markers and new opportunities to treat the early and advanced disease
In May, the European Commission extended the use of atezolizumab [...]
3105, 2021
Utility and use of NGS in clinical oncology: ESMO recommendations for patients with metastatic cancers
Last summer, the European Society of Medical Oncology (ESMO) published [...]
204, 2021
Europe approves the first anti-PD-L1/L1 therapy for patients with MSI-H/dMMR colorectal cancer
On January 26, 2021, the European Medicines Agency approved pembrolizumab [...]
2502, 2021
A breakthrough for the targeted therapy of RET+ tumours with new selective inhibitors
Last year the Food and Drug Administration approved two selective [...]
1612, 2020
Hope of a cure for cholangiocarcinoma coming from FGFR inhibitors
Last April, the Food and Drug Administration granted accelerated approval [...]
2809, 2020
Alpelisib and PIK3CA mutations: a new molecular targeted therapy for breast cancer is approved
On July 27, 2020, the European Medicines Agency authorised marketing [...]